Patient Derived Organoids

Patient Derived Organoids

Despite significant medical advancements, cancer remains a formidable challenge due to ineffective treatments and difficulties in predicting patient responses. Tumour heterogeneity, varying across cancer types, complicates drug efficacy. Cancer cell lines, while aiding research, often diverge from native tumours, impacting clinical trial success. Patient-derived xenograft (PDX) models better mimic primary tumours but face practical limitations. Tumour organoids, three-dimensional clusters derived from pluripotent stem cells, offer a promising alternative. Formed by embedding patient-derived tumours into a 3D matrix, organoids closely resemble primary tumour characteristics, presenting an advanced model for drug discovery and testing in cancer research.